|
RPA
|
|
Class 1
|
Age <65 y, KPS ≥ 70, controlled primary tumor, no extracranial metastases
|
|
Class 2
|
All patients not in Class I or III
|
|
Class 3
|
KPS < 70
|
|
GPA
|
| | | |
0
|
0,5
|
1
|
|
Age
| | |
> 60
|
50-59
|
<50
|
|
KPS
| | |
<70
|
70-80
|
90-100
|
|
Number of BM
| | |
> 3
|
2-3
|
1
|
|
Extracranial metastases
| | |
Yes
|
-
|
No
|
|
BS-BM
|
| | | | |
0
|
1
|
|
KPS
| | | |
50-70
|
80-100
|
|
Control of primary tumor
| | | |
No
|
Yes
|
|
Extracranial metastases
| | | |
Yes
|
No
|
|
Breast RPA
|
|
Class 1
|
1–2 brain metastases and extracranial disease absent or controlled and KPS 100
|
|
Class 2
|
All patients not in Class I or III
|
|
Class 3
|
Multiple brain metastases and KPS ≤ 60
|
|
Breast GPA
|
| |
0
|
0,5
|
1
|
1.5
|
2
|
|
Age
|
≥ 60
|
<60
| | | |
|
KPS
|
≤ 50
|
60
|
70-80
|
90-100
| |
|
Genetic subtype
|
Basal
| |
Luminal A
|
HER2
|
Luminal B
|
|
B: Clinico-biological parameters used for the P1PS and Le Scodan’s prognostic indexes.
|
|
P1PS
|
| | |
0
| |
1
| |
|
Sites of metastases
| |
0-2
| |
>2
| |
|
Serum LDH
| |
<ULN
| |
>ULN
| |
|
Albumin, g/L
| |
≥35
| |
<35
| |
|
Le Scodan Score
|
|
Class I
|
HER2+ tumors treated with trastuzumab
|
|
Class II
|
All patients not in Class I or III
|
|
Class III
|
Tumors not treated with trastuzumab and: lymphopenia at BM diagnosis or KPS < 70 and ≥ 50 years old at BM diagnosis or KPS ≥ 70 and triple negative tumors
|
